Laurus Labs Ltd

(LAURUSLABS)

Laurus Labs is a fully integrated pharmaceutical and biotechnology company with a leadership position in the production of generic active pharmaceutical ingredients (APIs) in high-growth therapeutic areas like antiretrovirals (ARVs), Hepatitis C, and Oncology. The company operates 4 manufacturing facilities in Visakhapatnam, Andhra Pradesh, and has invested significantly in their RD and manufacturing infrastructure, having launched 59 products since its inception in 2005. Its key customers include Aspen Pharmacare Limited, Aurobindo Pharma Limited, Cipla Limited, Mylan Laboratories Limited, NATCO Pharma, Strides Shasun, among others. It has 34 owned patents plus 152 pending patent applications in various countries. It is increasingly focused on their integrated generics finished dosage forms FDFs business, having acquired of Sriam Labs and Richcore Lifesciences in the recent years. During 2020, it launched Hydroxychloroquine, initiated TLD supplies for the Global Fund tender, and bargained partnerships with various private and public organizations. On 2022, it infused capital in Laurus Generics Inc . and infused around Rs 46 crore to acquire a stake in Immunoadoptive Cell Therapy Private Limited, among other expansions and operations.

Share Price: ₹580.70 per share as on 03 Dec, 2024 04:01 PM
Market Capitalisation: ₹31,098.71Cr as of today
Revenue: ₹1,223.70Cr as on September 2024 (Q3 24)
Net Profit: ₹17.72Cr as on September 2024 (Q3 24)
Listing date: 19 Dec, 2016
Chairperson Name: M V G Rao